Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
NCT ID: NCT06797362
Last Updated: 2026-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT06537310
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01357330
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVL-520
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement.
3. Previously received at least 1 prior ROS1 TKI, with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician.
4. Enrollment in a clinical trial of zidesamtinib is not possible.
5. Adequate organ function and bone marrow reserve.
Exclusion Criteria
2. Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol.
3. Ongoing anti-cancer therapy.
4. Eligible for ongoing clinical trial with zidesamtinib
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuvalent Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Anschutz School of Medicine
Aurora, Colorado, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
Manhattan, New York, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
GCS IUCT Oncopole
Toulouse, Occitanie, France
CHU de Nantes
Nantes, Pays de la Loire Region, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
IRCCS Istituto Tumori Giovanni Paolo II
Bari, , Italy
L'Istituto Europeo di Oncologia S.r.l.
Milan, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
IRCCS Istituto Oncologico Veneto
Padua, , Italy
AUSL della Romagna - Ravenna
Ravenna, , Italy
Istituto Nazionale Tumori "Regina Elena
Roma, , Italy
Antoni van Leeuwenhoek Hospital
Amsterdam, , Netherlands
Netherlands Cancer Institute: NKI
Amsterdam, , Netherlands
University Medical Center Groningen
Groningen, , Netherlands
National University Hospital Singapore
Singapore, , Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Uomi Cancer Center-Clinica Tres Torres
Barcelona, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Gregorio Marañón General University Hospital
Madrid, , Spain
Hospital Univ Doce de Octubre
Madrid, , Spain
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
The Royal Marsden Hospital
Sutton, Surrey, United Kingdom
The Royal Marsden Hospital
London, , United Kingdom
The Christie Hospital
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NVL-520-EAP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.